These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15261555)

  • 1. Immunotherapeutic approaches in multiple sclerosis.
    Adorini L
    J Neurol Sci; 2004 Aug; 223(1):13-24. PubMed ID: 15261555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective immunointervention in autoimmune diseases: lessons from multiple sclerosis.
    Adorini L
    J Chemother; 2001 Jun; 13(3):219-34. PubMed ID: 11450879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. The role of IFNbeta-1a in the treatment of multiple sclerosis.
    Pellegrini P; Totaro R; Contasta I; Berghella AM; Carolei A; Adorno D
    Neuroimmunomodulation; 2005; 12(4):220-34. PubMed ID: 15990453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunopathogenesis and immunotherapy of multiple sclerosis.
    Hemmer B; Nessler S; Zhou D; Kieseier B; Hartung HP
    Nat Clin Pract Neurol; 2006 Apr; 2(4):201-11. PubMed ID: 16932551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bystander modulation of chemokine receptor expression on peripheral blood T lymphocytes mediated by glatiramer therapy.
    Allie R; Hu L; Mullen KM; Dhib-Jalbut S; Calabresi PA
    Arch Neurol; 2005 Jun; 62(6):889-94. PubMed ID: 15956159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the TCR: T-cell receptor and peptide-specific tolerance-based strategies for restoring self-tolerance in CNS autoimmune disease.
    Kohm AP; Turley DM; Miller SD
    Int Rev Immunol; 2005; 24(5-6):361-92. PubMed ID: 16318987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New immunosuppressants with potential implication in multiple sclerosis.
    Gonsette RE
    J Neurol Sci; 2004 Aug; 223(1):87-93. PubMed ID: 15261567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of multiple sclerosis--2. Application of a new immunological basic research is close].
    Svenningsson A; Andersson M; Olsson T
    Lakartidningen; 1998 Dec; 95(49):5631-5. PubMed ID: 9863301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for the use of mitoxantrone in multiple sclerosis.
    Edan G; Morrissey S; Le Page E
    J Neurol Sci; 2004 Aug; 223(1):35-9. PubMed ID: 15261558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future immunotherapies in multiple sclerosis.
    Blevins G; Martin R
    Semin Neurol; 2003 Jun; 23(2):147-58. PubMed ID: 12894380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen-specific therapies in multiple sclerosis.
    Sospedra M; Martin R
    Int Rev Immunol; 2005; 24(5-6):393-413. PubMed ID: 16318988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy of multiple sclerosis.
    Weiner HL; Hafler DA
    Ann Neurol; 1988 Mar; 23(3):211-22. PubMed ID: 3288084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications.
    Becker Y
    Anticancer Res; 2006; 26(2A):1113-34. PubMed ID: 16619514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis.
    Tischner D; Weishaupt A; van den Brandt J; Müller N; Beyersdorf N; Ip CW; Toyka KV; Hünig T; Gold R; Kerkau T; Reichardt HM
    Brain; 2006 Oct; 129(Pt 10):2635-47. PubMed ID: 16921176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of mitoxantrone in multiple sclerosis--what is known?
    Neuhaus O; Kieseier BC; Hartung HP
    J Neurol Sci; 2004 Aug; 223(1):25-7. PubMed ID: 15261556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients.
    Kim HJ; Biernacki K; Prat A; Antel JP; Bar-Or A
    Clin Immunol; 2004 Apr; 111(1):38-46. PubMed ID: 15093550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis.
    Lim ET; Giovannoni G
    Expert Rev Neurother; 2005 May; 5(3):379-90. PubMed ID: 15938671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis?
    Jee Y; Liu R; Bai XF; Campagnolo DI; Shi FD; Vollmer TL
    Int Immunol; 2006 Apr; 18(4):537-44. PubMed ID: 16481342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glatiramer acetate: mechanisms of action in multiple sclerosis.
    Schrempf W; Ziemssen T
    Autoimmun Rev; 2007 Aug; 6(7):469-75. PubMed ID: 17643935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of tolerogenic dendritic cells by vitamin D receptor agonists.
    Adorini L; Penna G
    Handb Exp Pharmacol; 2009; (188):251-73. PubMed ID: 19031030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.